Topiramate: A novel therapeutic candidate for diabetes and aggression? positron emission tomography (PET) findings

Basit Öğe Kaydı
dc.authorid0000-0002-9704-6173
dc.authorid0000-0003-4292-5717
dc.authorid0000-0002-7685-2766
dc.authorid0000-0002-9815-1848
dc.contributor.authorYulu?, Burak
dc.contributor.authorHano?lu, Lütfü
dc.contributor.authorTavlı, Ahmet Mithat
dc.contributor.authorÇakır, Tansel
dc.contributor.authorOlmuşçelik, Oktay
dc.contributor.authorPaköz, Burak
dc.contributor.authorÜnlü, Gülşen
dc.date.accessioned2020-08-11T06:31:21Z
dc.date.available2020-08-11T06:31:21Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractBackground: There is still limited knowledge regarding the role of impaired brain glucose metabolism in the generation of aggression during diabetes. Additionally, there are rapidly replicating piece of evidence suggesting that topiramate may exert significant mood stabilizing effect. In this respect, we aimed to evaluate the neurometabolic correlates of the therapeutic effect of topiramate in a patient with diabetes and Intermittent explosive disorder (IED). Methods: We measured regional cerebral glucose metabolism using 2-[18F]-fluoro-2-deoxy-D-glucose and positron emission tomography (FDG-PET) in a diabetic patient with aggressive outbursts before and after treatment with topiramate. In order to reveal a defined information underlying the improvement of the aggressive symptoms we also combined the PET with Modified Overt Aggression Scale. Results: We have found that topiramate leads to the improvement in Modified Overt Aggression Scale that was well correlated with the increase in cortical brain metabolism. Discussion: The therapeutic role of topiramate may not only suggest secondary deficits due to diminished functions of the cortical part of emotional circuits but also indicate that diabetic individuals may be vulnerable to lower cerebral glucose metabolism in cortical regions. Further clinical trials that include well-conducted randomized controlled trials and cohort studies by using other methods (i.e., magnetic resonance spectroscopy and quantitative EEG analysis) are necessary to confirm our preliminary findings.
dc.identifier.citationYulu?, B., Hano?lu, L., Tavlı, A. M., Çakır, T., Olmuşçelik, O., Paköz, B. ve Ünlü, G. (2016). Topiramate: A novel therapeutic candidate for diabetes and aggression? positron emission tomography (PET) findings. Central Nervous System Agents in Medicinal Chemistry, 16(3), 227-230. https://dx.doi.org/10.2174/1871524916666160301102055
dc.identifier.doi10.2174/1871524916666160301102055
dc.identifier.endpage230
dc.identifier.issn1871-5249
dc.identifier.issue3
dc.identifier.scopusqualityQ3
dc.identifier.startpage227
dc.identifier.urihttps://dx.doi.org/10.2174/1871524916666160301102055
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5683
dc.identifier.volume16
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBentham Science Publishers
dc.relation.ispartofCentral Nervous System Agents in Medicinal Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTopiramate
dc.subjectTherapeutic Candidate
dc.subjectTomography
dc.titleTopiramate: A novel therapeutic candidate for diabetes and aggression? positron emission tomography (PET) findings
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu